Comparative Pharmacology
Head-to-head clinical analysis: NEO DELTA CORTEF versus NEO HYDELTRASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO DELTA CORTEF versus NEO HYDELTRASOL.
NEO-DELTA-CORTEF vs NEO-HYDELTRASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with potent anti-inflammatory, immunosuppressive, and antiallergic effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Prednisolone, a glucocorticoid, binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators, including cytokines, prostaglandins, and leukotrienes. It also inhibits phospholipase A2 and reduces immune cell activity.
1-2 drops into the conjunctival sac every 1-2 hours during the day and every 2 hours at night initially, then reduce frequency as inflammation subsides.
4-20 mg intramuscularly, intravenously, intra-articularly, or intrasynovially every 12-24 hours; maximum initial dose 40 mg.
None Documented
None Documented
Prednisolone: 2-4 hours; clinical context: adrenal suppression lasts 24-36 hours, requiring tapering
Terminal elimination half-life: 2.5–3.5 hours (adults). Note: The biologic half-life (duration of anti-inflammatory effect) is 18–36 hours due to persistence of glucocorticoid receptor-mediated effects.
Renal: 70-80% as metabolites; biliary: 10-15%; fecal: <5%
Renal: 50–80% as unchanged drug and metabolites (primarily as glucuronide and sulfate conjugates). Fecal/biliary: minor (<10%).
Category C
Category C
Corticosteroid with Antibiotic
Corticosteroid with Antibiotic